Article

Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastoma

2023-03-28

Abstract excerpt

<title>Abstract</title> <p>Treatment efficacy with chimeric antigen receptor (CAR) T cell therapy in glioblastoma (GBM) is undermined by an immunosuppressive tumor microenvironment (TME). We previously showed that CAR T cell therapy targeting epidermal growth factor receptor variant III (EGFRvIII) produces anti-tumor activity against recurrent GBM and causes upregulation of programmed death-ligand 1 (PD-L1) in th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 903e2de9-2efe-5553-bef7-7d8f39272aae
DOI: 10.21203/rs.3.rs-2742648/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastomaDOI 10.21203/rs.3.rs-2742648/v1Read

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaSemantic proximity Read

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trialsSemantic proximity Read

CAR T cell therapy for glioblastoma: A review of the first decade of clinical trialsSemantic proximity Read

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read

Immunogenetics of glioblastoma: the future of personalized patient managementSemantic proximity Read

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in GlioblastomaSemantic proximity Read

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read

A Bi-Specific T Cell-Engaging Antibody Triggers Protective Immune Memory and Glioma Microenvironment Remodeling in Immune Competent Preclinical ModelsSemantic proximity Read

Highly potent novel multi-armoured IL13Ra2 CAR-T subverts the immunosuppressive microenvironment of GlioblastomaSemantic proximity Read

Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in GlioblastomaSemantic proximity Read

Immune Cell Interplay in the Fight Against GBMSemantic proximity Read

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialSemantic proximity Read